ClinicalTrials.gg
CompletedNCT04937387Updated Aug 11, 2025Results posted

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

A Phase 3 interventional study of FF/VI and FF/UMEC/VI in Asthma, sponsored by GlaxoSmithKline. Completed at 61 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
13th of 40
359 · median 102
Started
2021
the only one that year
Phase 3
14 of 40
none open now
Registered
38th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 13th largest by enrollment, is the only one that started in 2021, is one of 14 in phase 3, and was the 38th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC/VI compared with FF/VI via ELLIPTA® inhaler in Chinese participants with inadequately controlled asthma. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
  • Fluticasone Furoate/Vilanterol (FF/VI)
  • ELLIPTA
  • Chinese
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Participant must be 18 years or older at the time of signing the .
  • Documented history asthma diagnosis as defined by the Global Initiative for Asthma (GINA) at least one year prior to Visit 0.
  • Participants with inadequately controlled asthma (ACQ-6 score >=1.5) despite Inhaled /Long-Acting Beta-2-Agonists (ICS/LABA) maintenance therapy at Visit 1.
  • Participants who require daily ICS/LABA for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total dose of ICS of greater than [>]250 micrograms (mcg) per day fluticasone propionate [FP, or equivalent]).
  • A best pre-bronchodilator morning (AM) >=30 percent (%) and less than (\<) 85% of the predicted normal value at Visit 1. Predicted values will be based upon the European Respiratory Society (ERS) Global Lung Function Initiative.
  • Airway reversibility defined as >=12% and >=200 milliliters (mL) increase in FEV1 between 20 and 60 minutes following 4 inhalations of albuterol/salbutamol aerosol at Visit 1.
  • All participants must be able to replace their current Short-Acting Beta-2-Agonists (SABA) inhaler with albuterol/salbutamol aerosol inhaler at Visit 1 as needed for the duration of the study. Participants must be judged capable of withholding albuterol/salbutamol for at least 6 hours prior to study visits.
  • Male or female participants following /barrier requirements and it should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non- (WONCBP) or a woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance during the study.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

  • Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.
  • Any asthma exacerbation requiring a change in maintenance asthma therapy in the 6 weeks prior to Visit 1.
  • Participants with the diagnosis of , as per Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, including all of the following:

    1. History of exposure to risk factors (especially tobacco smoke, occupational dusts and chemicals, smoke from home cooking and heating fuels).
    2. A post-albuterol/salbutamol FEV1/Forced Vital Capacity (FVC) ratio of \<0.70 and a post-albuterol/salbutamol FEV1 of less than or equal to (\<=)70% of predicted normal values.
    3. Onset of disease >=40 years of age.
  • Participants with current evidence of pneumonia, active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases or abnormalities other than asthma.
  • Immune suppression (e.g., [HIV], Lupus) or other risk factors for pneumonia (e.g., neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Participants at potentially high risk (e.g., very low [BMI], severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator.
  • Participants with historical or current evidence of cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Clinically significant (ECG) abnormality: Evidence of a clinically significant abnormality in the 12-lead ECG performed during screening. The Investigator will determine the clinical significance of each abnormal ECG finding in relation to the participant's medical history and exclude participants who would be at undue risk by participating in the trial. An abnormal and clinically significant finding is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following:

    1. Atrial Fibrillation with rapid ventricular rate >120 beats per minute (bpm).
    2. Sustained or non-sustained ventricular tachycardia.
    3. Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted).
    4. corrected for heart rate by Fridericia's formula (QTcF) >=500 milliseconds (msec) in participants with QRS \<120 msec and QTcF >=530 msec in participants with QRS >=120 msec.
  • Participants with any of the following at Screening (Visit 1):

    1. Myocardial infarction or unstable angina in the last 6 months.
    2. Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months.
    3. (NYHA) Class IV Heart failure [American Heart Association, 2016].
  • Participants with a medical condition such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy or bladder neck obstruction should only be included if in the opinion of the Investigator the benefit outweighs the risk and that the condition would not contraindicate study participation.
  • Participants with carcinoma that has not been in complete remission for at least 5 years. Participants who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the participant has been considered cured by treatment.
  • Participants with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
  • Participants who are medically unable to withhold their albuterol/salbutamol for the 6-hour period required prior to spirometry testing at each study visit.
  • Participants who are:

    1. Current smokers (defined as participants who have used inhaled tobacco products within the 12 months prior to Visit 1, e.g. cigarettes, electronic-cigarettes/vaping, cigars or pipe tobacco).
    2. Former smokers with a smoking history of >=10 pack years (e.g. >=20 cigarettes per day for 10 years).
  • Participants with a known or suspected history of alcohol or drug abuse within the last 2 years.
  • A history of allergy or to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate.
  • Participants at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
  • Study Investigators, sub-Investigators, study coordinators, employees of a participating Investigator or study site, or immediate family members of the aforementioned that is involved with this study.
  • In the opinion of the Investigator, any participant who is unable to read and/or would not be able to complete study related materials.

Inclusion criteria for randomization:

  • Participants with inadequately controlled asthma (ACQ-6 score >=1.5) at Visit 2.
  • A best pre-bronchodilator morning (AM) FEV1 >=30% and \<90% of the predicted normal value at Visit 2. Predicted values will be based upon the ERS Global Lung Function Initiative (Quanjer).
  • Liver function tests at Visit 1:

    1. (ALT) \<2 times (ULN).
    2. Alkaline phosphatase \<=1.5 times ULN.
    3. \<=1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Compliance with completion of the Electronic diary reporting defined as completion of all questions/assessment on >=4 of the last 7 days during the run-in period.

Exclusion criteria for randomization:

  • Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear during the run-in period that led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the participant's asthma status or the participant's ability to participate in the study.
  • Evidence of a severe exacerbation during screening or the run-in period, defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
  • Changes in asthma medication (excluding run-in medication and albuterol/salbutamol inhalation aerosol provided at Visit 1).
  • Evidence of clinically significant abnormal laboratory tests during screening or run-in which are still abnormal upon repeat analysis and are not believed to be due to disease(s) present. Each Investigator will use his/her own discretion in determining the clinical significance of the abnormality.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
359 participants (actual)

Study arms

  • Experimental
    Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler

    Drug: FF/VI · Device: ELLIPTA

  • Experimental
    Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler

    Drug: FF/UMEC/VI · Device: ELLIPTA

  • Experimental
    Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler

    Drug: FF/VI · Device: ELLIPTA

  • Experimental
    Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler

    Drug: FF/UMEC/VI · Device: ELLIPTA

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF)

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the highest FEV1 value obtained prior to the morning dose of investigational product. Baseline value is the latest acceptable assessment with non-missing value at the randomization visit (Visit 2).

    Time frame: Baseline (pre-dose at Day 1) and Week 12

Secondary outcomes

  1. Change From Baseline in Trough FEV1 at Week 12 (200ug FF)

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the highest FEV1 value obtained prior to the morning dose of investigational product. Baseline value is the latest acceptable assessment with non-missing value at the randomization visit (Visit 2)

    Time frame: Baseline (pre-dose at Day 1) and Week 12

  2. Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score at Week 12

    ACQ-7 is a 7-item questionnaire to assess asthma control in participants. Six attributes are measured with a patient-completed questionnaire, and the questions are designed to be self-completed by the participant. The six patient-reported questions enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/ limitation) scale. The recall period is the past week. The seventh attribute of the ACQ-7 is lung function (FEV1%-predicted) which was assessed via study visit spirometry. All 7 items of ACQ have response on 0-6 ordinal scale (0=no impairment/limitation, 6=total impairment/limitation). The total score is calculated as the average of all non-missing item responses, ranges from 0 to 6. Higher score indicates worst symptoms.

    Time frame: Baseline (pre-dose at Day 1) and Week 12

07

Results

Posted Aug 11, 2025

Participant flow

A total of 359 participants were randomized, however 1 participant was randomized in error and did not receive any study intervention. Therefore, 358 participants were included in 'Intent to Treat (ITT)' Population.

Participant flow — Overall Study
MilestoneFluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug
Started91908989
Safety90908988
Intent to treat (itt) population91908988
Completed88908686
Not completed3033
Withdrew: Adverse event1020
Withdrew: Lack of efficacy1001
Withdrew: Withdrawal by subject1011
Withdrew: Randomized in error0001

Outcome measures

PrimaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF)

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the highest FEV1 value obtained prior to the morning dose of investigational product. Baseline value is the latest acceptable assessment with non-missing value at the randomization visit (Visit 2).

Time frame:
Baseline (pre-dose at Day 1) and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF)
LitersFluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF)0.078 ± 0.03210.136 ± 0.0316
Statistical analysis
  • Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug · Least squares mean difference: 0.059 · 95% CI -0.030 to 0.147
  • Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug · Posterior mean: 0.076 · 90% CI 0.025 to 0.115Analysis was conducted in the Bayesian paradigm using the pre-specified mixture prior distribution, which was updated with the treatment difference between FF/UMEC/VI 100/62.5/25 and FF/VI 100/25 estimated in the MMRM analysis.
  • Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug · Posterior median: 0.079 · 95% CI 0.005 to 0.123Analysis was conducted in the Bayesian paradigm using the pre-specified mixture prior distribution, which was updated with the treatment difference between FF/UMEC/VI 100/62.5/25 and FF/VI 100/25 estimated in the MMRM analysis.
SecondaryChange From Baseline in Trough FEV1 at Week 12 (200ug FF)

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the highest FEV1 value obtained prior to the morning dose of investigational product. Baseline value is the latest acceptable assessment with non-missing value at the randomization visit (Visit 2)

Time frame:
Baseline (pre-dose at Day 1) and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Trough FEV1 at Week 12 (200ug FF)
LitersFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug
Change From Baseline in Trough FEV1 at Week 12 (200ug FF)0.121 ± 0.03190.116 ± 0.0325
Statistical analysis
  • Fluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug · Least squares mean difference: -0.005 · 95% CI -0.094 to 0.084
  • Fluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug · Posterior mean: 0.023 · 90% CI -0.071 to 0.103Analysis was conducted in the Bayesian paradigm using the pre-specified mixture prior distribution, which was updated with the treatment difference between FF/UMEC/VI 200/62.5/25 and FF/VI 200/25 estimated in the MMRM analysis.
  • Fluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug · Posterior median: 0.023 · 95% CI -0.086 to 0.110Analysis was conducted in the Bayesian paradigm using the pre-specified mixture prior distribution, which was updated with the treatment difference between FF/UMEC/VI 200/62.5/25 and FF/VI 200/25 estimated in the MMRM analysis.
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score at Week 12

ACQ-7 is a 7-item questionnaire to assess asthma control in participants. Six attributes are measured with a patient-completed questionnaire, and the questions are designed to be self-completed by the participant. The six patient-reported questions enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/ limitation) scale. The recall period is the past week. The seventh attribute of the ACQ-7 is lung function (FEV1%-predicted) which was assessed via study visit spirometry. All 7 items of ACQ have response on 0-6 ordinal scale (0=no impairment/limitation, 6=total impairment/limitation). The total score is calculated as the average of all non-missing item responses, ranges from 0 to 6. Higher score indicates worst symptoms.

Time frame:
Baseline (pre-dose at Day 1) and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score at Week 12
Scores on a scaleFluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug
Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score at Week 12-0.940 ± 0.0586-0.968 ± 0.0579-0.926 ± 0.0584-0.814 ± 0.0595
Statistical analysis
  • Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug · Least squares mean difference: -0.028 · 95% CI -0.190 to 0.134
  • Fluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ug vs Fluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug · Least squares mean difference: 0.112 · 95% CI -0.052 to 0.276

Adverse events

Collected over All-cause mortality, Non-serious AEs and serious AEs were collected up to approximately 12 weeks.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug0/91 (0%)2/90 (2.2%)16/90 (17.8%)
Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug0/90 (0%)3/90 (3.3%)18/90 (20%)
Fluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ug0/89 (0%)3/89 (3.4%)22/89 (24.7%)
Fluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug0/88 (0%)1/88 (1.1%)18/88 (20.5%)
Most frequent serious events
Most frequent serious events
EventFluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug
Type 2 diabetes mellitusMetabolism and nutrition disorders0/900/900/891/88
Vestibular neuronitisInfections and infestations0/900/901/890/88
Myocardial bridgingCongenital, familial and genetic disorders0/900/901/890/88
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/900/901/890/88
Hepatitis EInfections and infestations0/901/900/890/88
PneumoniaInfections and infestations0/901/900/890/88
EczemaSkin and subcutaneous tissue disorders1/901/900/890/88
AsthmaRespiratory, thoracic and mediastinal disorders1/900/900/890/88
Most frequent other events
Most frequent other events
EventFluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ug
Upper respiratory tract infectionInfections and infestations8/907/9010/894/88
COVID-19Infections and infestations5/903/905/895/88
NasopharyngitisInfections and infestations2/903/904/894/88
RhinitisInfections and infestations0/902/903/893/88
PyrexiaGeneral disorders1/901/901/893/88
PneumoniaInfections and infestations0/903/902/890/88

Baseline characteristics

Intent-to-Treat population includes all randomized participants, excluding-those who were randomized in error.

Age, Continuous
Age, Continuous(Years)Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ugTotal
Mean53.1 ± 11.552.6 ± 11.2250.7 ± 12.2349.9 ± 12.1951.6 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ugTotal
Female51485258209
Male40423730149
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug / Vilanterol [VI] 25 ugFluticasone Furoate [FF] 200 ug/ Umeclidinium [UMEC] 62.5 ug/Vilanterol [VI] 25 ugTotal
Asian- East Asian Heritage91908988358
08

Study locations

61 sites
  • GSK Investigational Site
    Beijing, 100020, China
  • GSK Investigational Site
    Changchun, 130021, China
  • GSK Investigational Site
    Changsha, 410013, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Chongqing, China
  • GSK Investigational Site
    Dongguan, 523059, China
  • GSK Investigational Site
    Fuzhou, 350005, China
  • GSK Investigational Site
    Guangzhou, 510120, China
  • GSK Investigational Site
    Guangzhou, 510150, China
  • GSK Investigational Site
    Guangzhou, 510180, China
  • GSK Investigational Site
    Guangzhou, 510280, China
  • GSK Investigational Site
    Guilin, 541001, China
  • GSK Investigational Site
    Guilin, 541002, China
  • GSK Investigational Site
    Hangzhou, 310005, China
  • GSK Investigational Site
    Hangzhou, 310006, China
  • GSK Investigational Site
    Hefei, 230001, China
  • GSK Investigational Site
    Hohhot, 010017, China
  • GSK Investigational Site
    Hohhot, 010050, China
  • GSK Investigational Site
    Huizhou, 516000, China
  • GSK Investigational Site
    Jiangmen, 529030, China
  • GSK Investigational Site
    Jinan, 250012, China
  • GSK Investigational Site
    Kunming, 650051, China
  • GSK Investigational Site
    Lanzhou, 730020, China
  • GSK Investigational Site
    Lianyungang, 222006, China
  • GSK Investigational Site
    Nanchang, 330038, China
  • GSK Investigational Site
    Nanjing, 210006, China
  • GSK Investigational Site
    Nanning, 530022, China
  • GSK Investigational Site
    Qingdao, 266071, China
  • GSK Investigational Site
    Qingyuan, 510030, China
  • GSK Investigational Site
    Qinhuangdao, 66000, China
  • GSK Investigational Site
    Sanya, 570311, China
  • GSK Investigational Site
    Sanya, China
  • GSK Investigational Site
    Shanghai, 200032, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 200090, China
  • GSK Investigational Site
    Shanghai, 200233, China
  • GSK Investigational Site
    Shanghai, 200433, China
  • GSK Investigational Site
    Shenyang, 110000, China
  • GSK Investigational Site
    Shenyang, 110004, China
  • GSK Investigational Site
    Shenzhen, 518020, China
  • GSK Investigational Site
    Shenzhen, 518036, China
  • GSK Investigational Site
    Shenzhen, 518053, China
  • GSK Investigational Site
    Shijiazhuang, 050000, China
  • GSK Investigational Site
    Taiyuan, 30000, China
  • GSK Investigational Site
    Tianjin, 300052, China
  • GSK Investigational Site
    Ürümqi, 830054, China
  • GSK Investigational Site
    Wenzhou, 323027, China
  • GSK Investigational Site
    Wuhan, 430060, China
  • GSK Investigational Site
    Wuhan, 430061, China
  • GSK Investigational Site
    Wuxi, 214023, China
  • GSK Investigational Site
    Xi'an, 710000, China
  • GSK Investigational Site
    Xiamen, 361004, China
  • GSK Investigational Site
    Xinxiang, 453004, China
  • GSK Investigational Site
    Xuzhou, 221006, China
  • GSK Investigational Site
    Yinchuan, 750004, China
  • GSK Investigational Site
    Zhanjiang, 524001, China
  • GSK Investigational Site
    Zhanjiang, 524045, China
  • GSK Investigational Site
    Zhengzhou, 450000, China
  • GSK Investigational Site
    Zhongshan, 528400, China
  • GSK Investigational Site
    Zunyi, 563114, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Aug 2024, 36 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 36 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2021
First posted
Jun 24, 2021
StartActual
Jul 29, 2021
Primary completionActual
Aug 5, 2024
CompletionActual
Aug 5, 2024
Results first posted
Aug 11, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04937387
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 24, 2021
Start date
Jul 29, 2021
Primary completion
Aug 5, 2024
Completion
Aug 5, 2024
Results posted
Aug 11, 2025
Last update
Aug 11, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol · GSK573719

Start the discussion